Therapix Biosciences Provides Portfolio Update
TEL AVIV, Israel, January 11, 2017 /PRNewswire/ —
Therapix Biosciences (OTCQB: THXBY) (TASE: THXBY.TA), a clinical-stage pharma company specializing in the development of cannabinoid-based drugs, reported that in its ongoing product portfolio review in order to maximize the potential value of product development, it has determined to advance one additional development program and to extend its Mild Cognitive Impairment (MCI) program. The additional program is in the area of antibiotic therapies, an area which we believe is in need of improved products.
The company’s objective is to use its “entourage effect” technology to enhance the efficacy of existing antibiotic drugs especially in antibiotic resistant conditions. Therapix’s “entourage effect” technology combines cannabinoids with the company’s proprietary endocannabinoid to enhance the effect of the cannabinoids while potentially improving the side-effect profile.
The second indication is an extension of the company’s current program using its proprietary ultra-low dose cannabinoid technology in MCI and will advance a development program on the treatment of cognitive impairment in sports-related brain injuries. These product development programs are in line with the company’s business strategy to create and expand a portfolio of cannabinoid-based treatments.
Therapix recently initiated a clinical proof-of-concept trial for the Company’s THX-TS01 which is in development for the treatment of Tourette’s syndrome.
Therapix is an Israeli-based clinical-stage pharma company focused on the development and commercialization of cannabinoid drugs. The company is listed on the Tel Aviv Stock Exchange and traded over-the counter (OTC) in the United States. Therapix’s CEO is Dr. Elran Haber and its Chairman is Dr. Ascher Shmulewitz.
Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.